In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a ...
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight ...
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight l ...
Velo3D is seeing renewed investor enthusiasm due to high-profile customers, a shift towards services, and an anticipated ...
But almost as quickly as they arrived on the scene, Russia’s oligarchs soon became political targets themselves. In the first decade of this century, with the tumult of the prior decade receding, ...
Professor Aaron Ames of the California Institute of Technology joins WIRED to answer the internet’s burning question about ...
Most people don't see it coming. They're walking their dog at dusk, letting the kids play in the backyard, or simply stepping ...
The project could affect endangered species like fairy shrimp, tadpole shrimp, and the California tiger salamander.
Q1 2026 Earnings Call April 28, 2026 5:00 PM EDTCompany ParticipantsStephen Haymore - Director of Investor RelationsAli El-Haj ...
No. 10 / 2026Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results